Greg M. Thurber

This paper uses an agent-based model to show that immune activation and target-independent mechanisms significantly contribute to the efficacy of the ADC T-DXd in cancer therapy.

This study develops HALA antibodies that adjust ADC delivery based on tumor HER2 expression, improving efficacy across varying expression levels in preclinical models.

The paper develops high-affinity, specific stapled peptides that inhibit Bcl-xL, showing 10 nM affinity and 100-fold selectivity over other Bcl-2 family members.